Women’s weight management involves unique hormonal, metabolic, and physiological factors that general telehealth platforms often overlook. The providers below specialize in women’s health — including hormone-aware care, PCOS management, and menopause support — and the guide beneath the table explains exactly what is different about GLP-1 weight loss for women in 2026.
Allara Health
Allara Health offers specialized care tailored to women's health needs. Rated 4.6/5.0 with insurance accepted at $149-$399.
WeightWatchers Clinic
WeightWatchers needs no introduction — the brand has been synonymous with weight management since 1963. Their clinic offering brings that decades-long behavioral science expertise into the GLP-1 er...
Midi Health
Midi Health offers specialized care tailored to women's health needs. Rated 4.5/5.0 with insurance accepted at Starting as low as $127/mo.
Hims/Hers
Hims/Hers is one of the most recognizable names in telehealth, and their entry into the GLP-1 weight loss space carries the weight of a publicly traded company with millions of users. Founded in 20...
Nurx
Nurx carved out its niche in telehealth by focusing on specialized care for women, and their expansion into GLP-1 weight management extends that patient-centered philosophy. Founded in 2015, the pl...
Belle
Belle is a GLP-1 telehealth provider founded in 2022 that offers compounded semaglutide and tirzepatide with pricing between $199 and $349 per month.
Brello Health
Brello Health entered the telehealth weight-loss market in 2023 with a distinctive angle: women-focused longevity medicine that pairs compounded GLP-1 medications with complementary vitamins. Their...
Prices and medications are as listed when each review was captured, mostly April 2026, and have not been re-checked since. Each review gives its date.
We may earn a commission if you purchase through links on this page, at no additional cost to you. This helps support our work.
What Makes GLP-1 Weight Loss Different for Women
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work the same way in everyone — they slow gastric emptying, blunt appetite, and improve insulin sensitivity. But the context in which they work is different for women. Female fat distribution, the monthly hormonal cycle, conditions like polycystic ovary syndrome (PCOS), the metabolic shifts of perimenopause, and contraception and pregnancy planning all change how a GLP-1 program should be run. Women also made up the majority of participants in the landmark weight-loss trials, so the headline efficacy numbers you have seen are, in large part, female results.
In the STEP 1 trial of semaglutide 2.4 mg, roughly three-quarters of participants were women, and the average participant lost about 15% of body weight over 68 weeks (Wilding et al., NEJM 2021). Tirzepatide pushed average loss higher still in SURMOUNT-1 (Jastreboff et al., NEJM 2022). The takeaway: these medications are highly effective for women — the nuances below are about doing it safely and choosing the right provider.
How Women Respond to GLP-1 Medications
On average, women lose a slightly higher percentage of body weight on GLP-1 therapy than men, partly because women tend to weigh less at baseline and partly due to differences in body composition. Women also report gastrointestinal side effects — nausea, constipation — somewhat more often, which is one reason a slow, patient dose titration matters more than rushing to the top dose. A good women’s provider treats the titration schedule as adjustable, not fixed.
Weight cycling across the menstrual cycle is normal — fluid shifts in the week before a period can mask real fat loss on the scale. Providers experienced with women’s health will coach patients to track trends over 4–6 weeks rather than reacting to day-to-day numbers.
GLP-1 for PCOS
Polycystic ovary syndrome affects roughly 1 in 10 women of reproductive age and is strongly linked to insulin resistance, making it one of the most compelling reasons a woman might pursue GLP-1 therapy. Beyond weight loss, GLP-1 medications improve insulin sensitivity and, in several studies, have been associated with improved menstrual regularity and ovulation in women with PCOS (PCOS + GLP-1 research on PubMed). None of the GLP-1 drugs are FDA-approved specifically for PCOS, so this is an off-label use that should be supervised by a clinician who understands the condition. Providers like Allara Health are built specifically around PCOS and women’s hormonal care.
GLP-1, Fertility, Pregnancy, and Birth Control
This is the most important safety section on this page. GLP-1 medications are not for use during pregnancy. Because semaglutide has a long half-life, the manufacturer advises discontinuing it at least 2 months before a planned pregnancy (Wegovy prescribing information, section 8.3, revised 06/2026). If you become pregnant unexpectedly while taking a GLP-1, contact your provider immediately.
There is also a contraception interaction women frequently aren’t told about: tirzepatide (Mounjaro, Zepbound) can reduce the effectiveness of oral birth control. The FDA label advises women using oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Semaglutide does not carry the same warning. A provider that specializes in women’s health should raise this proactively — if they don’t, ask.
GLP-1 During Perimenopause and Menopause
The hormonal shift of perimenopause and menopause drives a well-documented tendency toward weight gain, especially visceral (abdominal) fat, alongside falling muscle mass and a slower resting metabolism. GLP-1 therapy can be particularly useful in this window, but it works best paired with resistance training and adequate protein to protect muscle. Some women combine GLP-1 treatment with menopause-focused care; Midi Health is one provider that integrates menopause management with weight care. Always coordinate GLP-1 therapy with any hormone replacement therapy through a single clinician.
Dosing and Side Effects: What Women Should Know
The medications and FDA-approved doses are identical regardless of sex — there is no “women’s dose.” What differs is tolerance. Because women report nausea and GI effects somewhat more often, the practical advice is: titrate slowly, stay hydrated, eat smaller protein-forward meals, and don’t hesitate to pause at a lower dose that is working. To understand how these drugs work before you start, read our explainer on what GLP-1 medications are.
Choosing a GLP-1 Provider as a Woman
When comparing the providers in the table above, weight these factors: (1) does the intake ask about menstrual history, pregnancy plans, and contraception; (2) is there real clinician access for dose adjustments, not just a chatbot; (3) does the provider address PCOS or menopause explicitly if those apply to you; and (4) transparent pricing with no surprise lab or consultation fees. To compare every option side by side, use our full GLP-1 provider directory and our best overall providers ranking.
Frequently Asked Questions
Is semaglutide safe for women?
Yes, semaglutide (Wegovy, Ozempic) is FDA-approved and was studied in trial populations that were majority women. It is not safe during pregnancy and should be stopped at least 2 months before a planned pregnancy. Otherwise, the safety profile is the same for women as for men, with gastrointestinal side effects being the most common.
Does GLP-1 medication affect birth control?
Semaglutide does not. Tirzepatide (Mounjaro, Zepbound) can reduce the effectiveness of oral birth control, so the FDA advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and 4 weeks after each dose increase.
Can GLP-1 medications help with PCOS?
They are not FDA-approved for PCOS specifically, but because PCOS is driven by insulin resistance, GLP-1 medications can support weight loss and improved insulin sensitivity, and some studies report better menstrual regularity. Use should be supervised by a clinician familiar with PCOS.
Will GLP-1 help with menopause weight gain?
It can. Perimenopause and menopause promote visceral fat gain and muscle loss, and GLP-1 therapy addresses the weight component effectively — best combined with resistance training, adequate protein, and coordinated care if you are also on hormone replacement therapy.
Do women need a different GLP-1 dose than men?
No. The FDA-approved dosing schedules are the same regardless of sex. Because women report nausea slightly more often, a slower titration and staying at a well-tolerated effective dose is often the practical approach.
How we rank: Providers are ranked by our weighted scoring methodology across 8 categories. Rankings update automatically as new providers are reviewed and scores change. To learn more, visit our Review Methodology page.
Disclaimer: This guide is for informational purposes only and does not constitute medical advice. GLP-1 medications are not for use in pregnancy. Always consult your doctor before starting, stopping, or changing any GLP-1 medication, especially if you are pregnant, planning pregnancy, or breastfeeding.
